NCT02303821 2025-06-04
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Amgen
Phase 1 Completed
Amgen
Daiichi Sankyo
Pfizer
Sumitomo Pharma America, Inc.
Children's Oncology Group
Gilead Sciences
Pfizer